Q4 2013 13F Holders as of 12/31/2013
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
257M
-
Number of holders
-
379
-
Total 13F shares, excl. options
-
222M
-
Shares change
-
-74.9K
-
Total reported value, excl. options
-
$16.5B
-
Value change
-
-$5.66M
-
Put/Call ratio
-
1.38
-
Number of buys
-
7
-
Number of sells
-
-8
-
Price
-
$74.30
Significant Holders of VERTEX PHARMACEUTICALS INC / MA - Common Stock (VRTX) as of Q4 2013
412 filings reported holding VRTX - VERTEX PHARMACEUTICALS INC / MA - Common Stock as of Q4 2013.
VERTEX PHARMACEUTICALS INC / MA - Common Stock (VRTX) has 379 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 222M shares
of 257M outstanding shares and own 86.69% of the company stock.
Largest 10 shareholders include Capital World Investors (25.5M shares), WELLINGTON MANAGEMENT CO LLP (16.5M shares), VANGUARD GROUP INC (15.7M shares), JENNISON ASSOCIATES LLC (13.5M shares), State Street Corp (9.64M shares), PRICE T ROWE ASSOCIATES INC /MD/ (9.36M shares), JPMORGAN CHASE & CO (9.18M shares), Ameriprise Financial Inc (7.79M shares), Clearbridge Investments, LLC (6.9M shares), and BlackRock Institutional Trust Company, N.A. (5.99M shares).
This table shows the top 379 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.